
Protalix BioTherapeutics, Inc. (NYSE:PLX – Free Report) – Investment analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Protalix BioTherapeutics in a report released on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.28 for the year, down from their prior estimate of $0.29. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2027 earnings at $0.02 EPS.
Protalix BioTherapeutics Stock Performance
NYSE PLX opened at $3.05 on Thursday. Protalix BioTherapeutics has a one year low of $1.65 and a one year high of $3.19. The stock has a 50-day moving average of $2.69 and a 200 day moving average of $2.45. The company has a market capitalization of $245.74 million, a price-to-earnings ratio of -23.46 and a beta of 0.01.
Institutional Investors Weigh In On Protalix BioTherapeutics
Protalix BioTherapeutics Company Profile
Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.
Read More
- Five stocks we like better than Protalix BioTherapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
